NDA 021314 · Meridian Bioscience
Idkit:Hp
Citric Acid, Urea C-13 · Oral · Helicobacter pylori Diagnostic
Last checked: Nov 20, 2026Latest source record: Jul 24, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2002
Dec 17, 2002
Approved uses
2
Original approval plus efficacy supplements
Registered trials
516
148 Phase 3, 44 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jul 28, 2026.
IDkit Hp ® One and IDkit Hp ® Two are indicated for use as a diagnostic aid in the initial diagnosis and post-treatment monitoring of Helicobacter pylori (H. pylori) infection in adults and pediatric patients 3 years of age and older. IDkit Hp One and IDkit Hp Two are to be administered only by trained personnel as ordered by a licensed healthcare practitioner using the BreathID ® system device as identified in the BreathID ® system device labeling. IDkit Hp One and IDkit Hp Two are indicated for use as a diagnostic aid in the initial diagnosis and post-treatment monitoring of Helicobacter pylori (H. pylori) infection in adults and pediatric patients 3 years of age and older. ( 1 ) IDkit Hp One and IDkit Hp Two are to be administered only by trained personnel as ordered by a licensed healthcare practitioner using the BreathID ® system device as identified in the BreathID ® system device labeling. ( 1 )
Mechanism: IDkit Hp One and IDkit Hp Two are administered using the BreathID system device, a non-invasive breath test that analyzes a breath sample before and after ingestion of 13 C- urea and citric acid. 75 mg 13 C-urea and 4. g citric acid is dissolved in water and administered orally to the patient. The presence of citric acid creates an acidic environment in the stomach and delays the gastric emptying of the ingested solution to the duodenum. These two characteristics facilitate the decomposition of the urea by H. pylori , if present. Thus, in the presence of urease produced by gastric H. pylori ,...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jul 24, 2026 Supplement 14 · Efficacy LetterLabel
- Dec 17, 2002 Original approval · Type 3 - New Dosage Form ReviewLetterLabel
1 products under this application
- IDKIT:HP · CITRIC ACID 4GM; UREA C-13 75MG · FOR SOLUTION, TABLET, FOR SOLUTION, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Citric Acid" as an intervention, any sponsor and status, largest first.
- Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)Active, not recruiting
National Cancer Institute (NCI)NIH
NCT02194738 · 7,458 participants · Start Sep 26, 2014 · Primary completion Dec 3, 2025
Drug: Carboplatin; Cisplatin and 8 more · For: Stage IB Lung Non-Small Cell Carcinoma AJCC v7; Stage II Lung Non-Small Cell Cancer AJCC v7; Stage IIA Lung Cancer AJCC v8 and 4 more
Sites: Birmingham, Alabama; Daphne, Alabama; Mobile, Alabama · 1,660 sites in all
- Tamoxifen, Ovarian Ablation, and/or Chemotherapy in Treating Women With Stage I, Stage II, or Stage IIIA Breast CancerPivotal-lookingCompleted
Institute of Cancer Research, United KingdomAcademic, hospital or other
NCT00002582 · 6,000 participants (planned) · Start Jun 1993
Drug: CMF regimen; cyclophosphamide and 6 more · For: Breast Cancer
Sites: Birmingham, United Kingdom; Glasgow, United Kingdom
- Routine Use of Potassium Competitive Acid Blocker vs. Guideline-Directed Gastrointestinal Protection Strategy in Acute Myocardial InfarctionPivotal-lookingRecruiting
Samsung Medical CenterAcademic, hospital or other
NCT07467213 · 5,000 participants (planned) · Start Jun 23, 2026 · Primary completion Dec 31, 2029
Drug: Zastaprazan; Proton Pump Inhibitors (PPI) · For: Acute Myocardial Infarction (AMI); Gastrointestinal Bleeding
Sites: Seoul, South Korea
- Doxorubicin Hydrochloride, Cyclophosphamide, and Pacltaxel With or Without Trastuzumab in Treating Women With HER2-Positive Node-Positive or High-Risk Node-Negative Breast CancerPivotal-lookingCompleted
National Cancer Institute (NCI)NIH
NCT00005970 · 3,436 participants · Start May 19, 2000 · Primary completion Apr 25, 2005
Drug: Aromatase Inhibition Therapy; Cyclophosphamide and 4 more · For: Breast Adenocarcinoma; HER2 Positive Breast Carcinoma; Stage IA Breast Cancer AJCC v7 and 4 more
Sites: Birmingham, Alabama; Phoenix, Arizona; Scottsdale, Arizona · 157 sites in all
- Study of Contraceptive Efficacy & Safety of Phexxi™ (Previously Known as Amphora) Gel Compared to Conceptrol Vaginal GelPivotal-lookingCompleted
Evofem Inc.Industry
NCT01306331 · 3,389 participants · Start Apr 2011 · Primary completion Jun 2014
Drug: Conceptrol; Amphora · For: Contraception
Sites: Birmingham, Alabama; Little Rock, Arkansas; Anaheim, California · 52 sites in all
- Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast CancerPivotal-lookingCompleted
ETOP IBCSG Partners FoundationResearch network
NCT00066690 · 3,066 participants · Start Dec 17, 2003 · Primary completion May 2014
Drug: Exemestane; Tamoxifen and 1 more · For: Estrogen Receptor Positive Breast Cancer; Progesterone Receptor Positive Tumor; Recurrent Breast Carcinoma and 5 more
Sites: Birmingham, Alabama; Anchorage, Alaska; Scottsdale, Arizona · 500 sites in all
- Combination Chemotherapy and Trastuzumab in Treating Women With Stage I, Stage II, or Stage III HER2-Positive Breast CancerPivotal-lookingStatus unknown
Azienda Ospedaliero-Universitaria di ModenaAcademic, hospital or other
NCT00629278 · 2,500 participants (planned) · Start Dec 2007 · Primary completion Dec 2010
Drug: trastuzumab; aromatase inhibition therapy and 8 more · For: Breast Cancer
Sites: Cuneo, Italy; Ivrea, Italy; Modena, Italy · 6 sites in all
- Safety and Effectiveness of Tenofovir Gel in the Prevention of Human Immunodeficiency Virus (HIV-1) Infection in Women and the Effects of Tenofovir Gel on the Incidence of Herpes Simplex Virus (HSV-2) InfectionPivotal-lookingCompleted
CONRADAcademic, hospital or other
NCT01386294 · 2,059 participants · Start Oct 2011 · Primary completion Aug 2014
Drug: Tenofovir gel; Universal placebo gel · For: HIV Prevention
Sites: Pietermaritzburg, South Africa; Cape Town, South Africa; Diepkloof, South Africa · 9 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- [Not Available].
Pereira LGS, Bezerra SJC, Viana ÍEL, et al. · Braz Dent J 2022 · Randomized Controlled Trial
- Effect of an experimental TiF4/NaF solution in preventing tooth erosion.
Vertuan M, da Silva JF, de Souza BM, et al. · Arch Oral Biol 2024 · Randomized Controlled Trial
- Toothpaste containing TiF4 and chitosan against erosive tooth wear in situ.
Francese MM, Urasaki BAN, de Barros MC, et al. · J Dent 2024 · Randomized Controlled Trial, Comparative Study
- Fluoride varnishes supplemented with nano-sized sodium trimetaphosphate reduce enamel erosive wear in vitro.
Paiva MF, Delbem ACB, Veri IV, et al. · J Dent 2023 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- A Randomized Controlled Trial Comparing a New D-Mannose-based Dietary Supplement to Placebo for the Treatment of Uncomplicated Escherichia coli Urinary Tract Infections.
Salvatore S, Ruffolo AF, Stabile G, et al. · Eur Urol Focus 2023 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Designing mouthwash formulations with innovative molecular components to control initial dental erosion in vivo.
Pelá VT, de Brito MM, da Silva GC, et al. · Clin Oral Investig 2024 · Randomized Controlled Trial
Sponsor: Meridian Bioscience
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.